A Phase II, Open Label Trial of a Vaccine (FSME-IMMUN 0.5 mL) Against Tick-Borne Encephalitis (TBE) for NIAID Workers Manipulating Tick-Borne Encephalitis Virus (TBEV) in the Laboratory
Phase of Trial: Phase II
Latest Information Update: 20 May 2017
At a glance
- Drugs Tick-borne encephalitis vaccine (Primary)
- Indications Encephalitis virus infections
- Focus Pharmacodynamics
- 24 Dec 2016 Status changed from recruiting to discontinued.
- 12 Jan 2016 Planned End Date changed from 1 Jan 2030 to 1 Nov 2020, as reported by ClinicalTrials.gov record.
- 12 Jan 2016 Planned primary completion date changed from 1 Jan 2030 to 1 Nov 2020, as reported by ClinicalTrials.gov record.